Email Updates

You are here

HPTN 059

Status
Completed
Phase
II
Principal Investigator(s)
Sharon Hillier, PhD; Jessica Justman, MD; Smita N. Joshi, MBBS; Craig Hoesley, MD
Objective

The purpose of this study is to determine the safety and acceptability of a vaginal microbicide in HIV uninfected sexually active women.

 

Last updated May 16, 2021

Prevention Option(s)
Microbicides
Observational
Prospective Cohort
Study Design
Controlled
Placebo
Double-blind
Arms and Assigned Interventions
Description
Drug: 1% tenofovir gel
Mode of Delivery
Gel
Products
1% tenofovir gel
Trial Sponsors
NIAID (DAIDS-ES: 10145)
October 2007
Enrollment
200
18
Years
50
Years
Population
Women
Sites

Alabama Microbicide CRS

Birmingham, Alabama
United States of America

Bronx-Lebanon Hospital

New York, New York
United States of America

NARI Pune

Pune, Maharashtra
India